Selected research
Industry Growth & Trends
Global Depression-MDD Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Depression-MDD Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Depression-MDD Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Depression-MDD Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Depression-MDD Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Depression-MDD Drugs market include Merck, Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical Industries, Reviva Pharmaceuticals Holdings, Janssen Pharmaceuticals and H. Lundbeck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Depression-MDD Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Depression-MDD Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Depression-MDD Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Depression-MDD Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Depression-MDD Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Depression-MDD Drugs Market by Company
Merck
Eli Lilly
Pfizer
GlaxoSmithKline
AstraZeneca
Teva Pharmaceutical Industries
Reviva Pharmaceuticals Holdings
Janssen Pharmaceuticals
H. Lundbeck
Bristol-Myers Squibb
Depression-MDD Drugs Segment by Type
Selective Serotonin Reuptake Inhibitors,
Tricyclic Antidepressants
Atypical Antidepressants
Serotonin & Norepinephrine Reuptake Inhibitors
Depression-MDD Drugs Segment by Application
Online Pharmacy
Pharmacy
Hospital
Other
Depression-MDD Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Depression-MDD Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Depression-MDD Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Depression-MDD Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Depression-MDD Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Selective Serotonin Reuptake Inhibitors,
- Tricyclic Antidepressants
- Atypical Antidepressants
- Serotonin & Norepinephrine Reuptake Inhibitors
Applications
- Online Pharmacy
- Pharmacy
- Hospital
- Other
Companies covered
- Merck
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Teva Pharmaceutical Industries
- Reviva Pharmaceuticals Holdings
- Janssen Pharmaceuticals
- H. Lundbeck
- Bristol-Myers Squibb
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Depression-MDD Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Depression-MDD Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Depression-MDD Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Depression-MDD Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Depression-MDD Drugs Market Size (2021-2032)
- 1.5.1 North America Depression-MDD Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Depression-MDD Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Depression-MDD Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Depression-MDD Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Depression-MDD Drugs Market Size Growth Rate (2021-2032)
2 Depression-MDD Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Selective Serotonin Reuptake Inhibitors,
- 2.1.2 Tricyclic Antidepressants
- 2.1.3 Atypical Antidepressants
- 2.1.4 Serotonin & Norepinephrine Reuptake Inhibitors
- 2.2 Global Depression-MDD Drugs Market Size by Type
- 2.2.1 Global Depression-MDD Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Depression-MDD Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Depression-MDD Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Depression-MDD Drugs Market Size by Regions
- 2.3.1 North America Depression-MDD Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Depression-MDD Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Depression-MDD Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Depression-MDD Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Depression-MDD Drugs Market Size Breakdown by Type (2021-2026)
3 Depression-MDD Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Online Pharmacy
- 3.1.2 Pharmacy
- 3.1.3 Hospital
- 3.1.4 Other
- 3.2 Global Depression-MDD Drugs Market Size by Application
- 3.2.1 Global Depression-MDD Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Depression-MDD Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Depression-MDD Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Depression-MDD Drugs Market Size by Regions
- 3.3.1 North America Depression-MDD Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Depression-MDD Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Depression-MDD Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Depression-MDD Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Depression-MDD Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Depression-MDD Drugs Industry Trends
- 4.2 Depression-MDD Drugs Industry Drivers
- 4.3 Depression-MDD Drugs Industry Opportunities and Challenges
- 4.4 Depression-MDD Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Depression-MDD Drugs Revenue (2021-2026)
- 5.2 Global Depression-MDD Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Depression-MDD Drugs Key Company Headquarters & Area Served
- 5.4 Global Depression-MDD Drugs Company, Product Type & Application
- 5.5 Global Depression-MDD Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Depression-MDD Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Depression-MDD Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Depression-MDD Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Merck
- 6.1.1 Merck Company Information
- 6.1.2 Merck Business Overview
- 6.1.3 Merck Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Merck Depression-MDD Drugs Product Portfolio
- 6.1.5 Merck Recent Developments
- 6.2 Eli Lilly
- 6.2.1 Eli Lilly Company Information
- 6.2.2 Eli Lilly Business Overview
- 6.2.3 Eli Lilly Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Eli Lilly Depression-MDD Drugs Product Portfolio
- 6.2.5 Eli Lilly Recent Developments
- 6.3 Pfizer
- 6.3.1 Pfizer Company Information
- 6.3.2 Pfizer Business Overview
- 6.3.3 Pfizer Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Pfizer Depression-MDD Drugs Product Portfolio
- 6.3.5 Pfizer Recent Developments
- 6.4 GlaxoSmithKline
- 6.4.1 GlaxoSmithKline Company Information
- 6.4.2 GlaxoSmithKline Business Overview
- 6.4.3 GlaxoSmithKline Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 GlaxoSmithKline Depression-MDD Drugs Product Portfolio
- 6.4.5 GlaxoSmithKline Recent Developments
- 6.5 AstraZeneca
- 6.5.1 AstraZeneca Company Information
- 6.5.2 AstraZeneca Business Overview
- 6.5.3 AstraZeneca Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 AstraZeneca Depression-MDD Drugs Product Portfolio
- 6.5.5 AstraZeneca Recent Developments
- 6.6 Teva Pharmaceutical Industries
- 6.6.1 Teva Pharmaceutical Industries Company Information
- 6.6.2 Teva Pharmaceutical Industries Business Overview
- 6.6.3 Teva Pharmaceutical Industries Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Teva Pharmaceutical Industries Depression-MDD Drugs Product Portfolio
- 6.6.5 Teva Pharmaceutical Industries Recent Developments
- 6.7 Reviva Pharmaceuticals Holdings
- 6.7.1 Reviva Pharmaceuticals Holdings Company Information
- 6.7.2 Reviva Pharmaceuticals Holdings Business Overview
- 6.7.3 Reviva Pharmaceuticals Holdings Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Reviva Pharmaceuticals Holdings Depression-MDD Drugs Product Portfolio
- 6.7.5 Reviva Pharmaceuticals Holdings Recent Developments
- 6.8 Janssen Pharmaceuticals
- 6.8.1 Janssen Pharmaceuticals Company Information
- 6.8.2 Janssen Pharmaceuticals Business Overview
- 6.8.3 Janssen Pharmaceuticals Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Janssen Pharmaceuticals Depression-MDD Drugs Product Portfolio
- 6.8.5 Janssen Pharmaceuticals Recent Developments
- 6.9 H. Lundbeck
- 6.9.1 H. Lundbeck Company Information
- 6.9.2 H. Lundbeck Business Overview
- 6.9.3 H. Lundbeck Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 H. Lundbeck Depression-MDD Drugs Product Portfolio
- 6.9.5 H. Lundbeck Recent Developments
- 6.10 Bristol-Myers Squibb
- 6.10.1 Bristol-Myers Squibb Company Information
- 6.10.2 Bristol-Myers Squibb Business Overview
- 6.10.3 Bristol-Myers Squibb Depression-MDD Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Bristol-Myers Squibb Depression-MDD Drugs Product Portfolio
- 6.10.5 Bristol-Myers Squibb Recent Developments
7 North America
- 7.1 North America Depression-MDD Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Depression-MDD Drugs Market Size by Country (2021-2026)
- 7.3 North America Depression-MDD Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Depression-MDD Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Depression-MDD Drugs Market Size by Country (2021-2026)
- 8.3 Europe Depression-MDD Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Depression-MDD Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Depression-MDD Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Depression-MDD Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Depression-MDD Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Depression-MDD Drugs Market Size by Country (2021-2026)
- 10.3 South America Depression-MDD Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Depression-MDD Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Depression-MDD Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Depression-MDD Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst